Highlights from Previous Meetings:

Ø Philip Teitelbaum, The Role of Drug Metabolism in Drug Discovery Support and Compound Development, Covance

Ø Presentation from Ron Steigerwalt, Ph.D., DABT - Working With the FDA: Perspectives of a Former Reviewer

Ø Laura Dorsey, Washington Technology Center - "Funding Resources"

Ø Loretta Little, WRF Capital - "Creating an Early Stage Company"

Ø Jeff Engelhardt, Amgen – What has the TGN 1412 Incident Done for the Conduct of Phase 1 Studies in Europe?

Home Page